Literature DB >> 7957506

Influence of digoxin-like immunoreactive factor on late complications in patients with diabetes mellitus.

R H Straub1, R Elbracht, B K Krämer, M Roth, K D Palitzsch, J Schölmerich.   

Abstract

The aim of this study was to compare the intensity of typical late complications in diabetic patients (n = 65, 28 type I, 37 type II) who were not on glycoside drugs with low vs. high serum levels of digoxin-like immunoreactive factor (DLIF: group I, n = 42, DLIF < or = the detection limit of 0.2 ng ml-1; and group II, n = 23, mean +/- SEM: 1.17 +/- 0.31 [0.25-4.96] ng ml-1). For detection of nephropathy, urinary albumin excretion (24 h) and creatinine clearance tests were used. For coronary heart disease a questionnaire and standard ECG; for peripheral occlusive vascular disease a questionnaire; for eye disease a fundoscopy; for neuropathy a neurological score system; and for autonomic neuropathy a standardized test battery was employed. Patients with high DLIF levels showed better test results in vibratory perception (95.7 +/- 1.5 vs. 82.8 +/- 3.8%, normal finding = 100%, 2p = 0.016), had better percentile localizations concerning maximal pupillary area in darkness (28.4 +/- 6.6 vs. 8.1 +/- 1.8%, 2p = 0.0004), contraction velocity at 1 s (21.5 +/- 5.8 vs. 8.0 +/- 2.2%, 2p = 0.012), and dilation velocity at 6 s (23.0 +/- 6.8 vs. 10.5 +/- 2.5%, 2p = 0.041), had less retinopathy (with retinopathy: 26.1% vs. 64.3%, 2p = 0.0028), and better percentile localizations in the respiratory sinus arrhythmia test (68.4 +/- 7.3 vs. 44.1 +/- 4.9%, 2p = 0.0064). There was no difference concerning nephropathy, blood pressure, coronary heart disease and peripheral vascular disease. Separate analysis according to the type of diabetes confirmed the results in each group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957506     DOI: 10.1111/j.1365-2362.1994.tb02379.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

Review 1.  Diabetic neuropathy: clinical manifestations and current treatments.

Authors:  Brian C Callaghan; Hsinlin T Cheng; Catherine L Stables; Andrea L Smith; Eva L Feldman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

2.  Cardiotonic Steroids Induce Vascular Fibrosis Via Pressure-Independent Mechanism in NaCl-Loaded Diabetic Rats.

Authors:  Olga V Fedorova; Artem V Fadeev; Yulia N Grigorova; Courtney A Marshall; Valentina Zernetkina; Nikolai I Kolodkin; Natalia I Agalakova; Alexandra O Konradi; Edward G Lakatta; Alexei Y Bagrov
Journal:  J Cardiovasc Pharmacol       Date:  2019-11       Impact factor: 3.105

Review 3.  The metabolic syndrome and neuropathy: therapeutic challenges and opportunities.

Authors:  Brian Callaghan; Eva Feldman
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.